Back to Search Start Over

Author Correction: CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia

Authors :
Zhao, Ze-an
Jiang, Yu
Chen, Yan-yu
Wu, Ting
Lan, Qun-sheng
Li, Yong-mei
Li, Lu
Yang, Yang
Lin, Cui-ting
Cao, Ying
Zhou, Ping-zheng
Guo, Jia-yin
Tian, Yuan-xin
Pang, Jian-xin
Source :
Acta Pharmacol Sin
Publication Year :
2022
Publisher :
Springer Science and Business Media LLC, 2022.

Abstract

Urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) are important targets for the development of uric acid-lowering drugs. We previously showed that the flexible linkers of URAT1 inhibitors could enhance their potency. In this study we designed and synthesized CDER167, a novel RDEA3710 analogue, by introducing a linker (methylene) between the naphthalene and pyridine rings to increase flexibility, and characterized its pharmacological and pharmacokinetics properties in vitro and in vivo. We showed that CDER167 exerted dual-target inhibitory effects on both URAT1 and GLUT9: CDER167 concentration-dependently inhibited the uptake of [

Details

ISSN :
17457254 and 16714083
Volume :
43
Database :
OpenAIRE
Journal :
Acta Pharmacologica Sinica
Accession number :
edsair.doi.dedup.....f8963820aa6ea01b80dbf9778ee28852